|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating activities: | |||||
| Consolidated net income | |||||
| Adjustments to reconcile consolidated net income to net cash provided by operating activities: | |||||
| Depreciation and amortization | |||||
| Stock-based compensation expense | |||||
| Deferred income taxes | |||||
| (Gain) on sale of asset | |||||
| (Gain) on divestiture | |||||
| Gain on fair market value adjustment and gain on sale of equity investments | |||||
| Changes in assets and liabilities, excluding effects of acquisitions: | |||||
| Accounts receivable, net | |||||
| Other assets, current and long-term | |||||
| Current and long-term liabilities, excluding debt | |||||
| Cash provided by operating activities | |||||
| Investing activities: | |||||
| Capital expenditures | |||||
| Acquisitions, net of cash acquired | |||||
| Cash received from sale of asset | |||||
| Cash received from divestitures | |||||
| Cash used in investing activities | |||||
| Financing activities: | |||||
| Net short-term borrowings (payments) | |||||
| Payments on long-term debt | |||||
| Proceeds from issuance of long-term debt | |||||
| Treasury stock purchases | |||||
| Dividends paid to Equifax shareholders | |||||
| Distributions paid to noncontrolling interests | |||||
| Proceeds from exercise of stock options and employee stock purchase plan | |||||
| Payment of taxes related to settlement of equity awards | |||||
| Purchase of redeemable noncontrolling interests | |||||
| Debt issuance costs | |||||
| Cash used in financing activities | |||||
| Effect of foreign currency exchange rates on cash and cash equivalents | |||||
| Increase (decrease) in cash and cash equivalents | |||||
| Cash and cash equivalents, beginning of period | |||||
| Cash and cash equivalents, end of period | |||||
Loading...
